Literature DB >> 21484382

Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Stephan Walrand1, Glenn D Flux, Mark W Konijnenberg, Roelf Valkema, Eric P Krenning, Renaud Lhommel, Stanislas Pauwels, Francois Jamar.   

Abstract

This paper reviews issues concerning (86)Y positron emission tomography (PET), (90)Y PET and (90)Y bremsstrahlung imaging. Specific methods and corrections developed for quantitative imaging, for application in preclinical and clinical studies, and to assess (90)Y dosimetry are discussed. The potential imaging capabilities with the radioisotopes (87)Y and (88)Y are also considered. Additional studies required to assess specific unaddressed issues are also identified.

Mesh：

Substances：

Year:  2011        PMID： 21484382     DOI： 10.1007/s00259-011-1771-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  89 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

Review 2.  Radiotherapy quality assurance by individualized in vivo dosimetry: state of the art.

Authors:  A Ismail; J-Y Giraud; G N Lu; R Sihanath; P Pittet; J M Galvan; J Balosso
Journal:  Cancer Radiother       Date:  2009-03-09       Impact factor: 1.018

3.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

4.  Experimental radiotherapy of a rat rhabdomyosarcoma with 15 meV neutrons and 300 kV x-rays. II. Effects of ractionated treatments, applied five times a week for several weeks.

Authors:  G W Barendsen; J J Broerse
Journal:  Eur J Cancer       Date:  1970-04       Impact factor: 9.162

5.  Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.

Authors:  F Rösch; H Herzog; C Plag; B Neumaier; U Braun; H W Müller-Gärtner; G Stöcklin
Journal:  Eur J Nucl Med       Date:  1996-08

6.  (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Authors:  Lars R Perk; Gerard W M Visser; Maria J W D Vosjan; Marijke Stigter-van Walsum; Bernard M Tijink; C René Leemans; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

7.  Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.

Authors:  Stig Palm; Richard M Enmon; Cornelia Matei; Katherine S Kolbert; Su Xu; Pat B Zanzonico; Ronald L Finn; Jason A Koutcher; Steven M Larson; George Sgouros
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

8.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

9.  Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.

Authors:  Manuel J Koppe; Robert P Bleichrodt; Annemieke C Soede; Albert A Verhofstad; David M Goldenberg; Wim J G Oyen; Otto C Boerman
Journal:  J Nucl Med       Date:  2004-07       Impact factor: 10.057

10.  Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.

Authors:  D A Goodwin; C F Meares; M Osen
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057
View more
  29 in total

Review 1.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

2.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

Review 3.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.

Authors:  Eric W Price; Kimberly J Edwards; Kathryn E Carnazza; Sean D Carlin; Brian M Zeglis; Michael J Adam; Chris Orvig; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2016-06-28       Impact factor: 2.408

5.  The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects.

Authors:  Hojjat Ahmadzadehfar; Marianne Muckle; Amir Sabet; Kai Wilhelm; Christiane Kuhl; Kim Biermann; Torjan Haslerud; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

6.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

Review 7.  Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  David Taïeb; Philippe Garrigue; Manuel Bardiès; Ahmad Esmaeel Abdullah; Karel Pacak
Journal:  PET Clin       Date:  2015-07-08

8.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

9.  Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy.

Authors:  Stephan Walrand; Renaud Lhommel; Pierre Goffette; Marc Van den Eynde; Stanislas Pauwels; François Jamar
Journal:  EJNMMI Res       Date:  2012-05-19       Impact factor: 3.138

Review 10.  Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Authors:  B L R Kam; J J M Teunissen; E P Krenning; W W de Herder; S Khan; E I van Vliet; D J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.